Center-Authored Papers

Filters: Author is Tangen, Catherine M  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Thompson IM, Tangen CM, Parnes HL, Lippman SM, Coltman CA.  2008.  Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology. 71(5):854-7. Abstract
Redman MW, Tangen CM, Goodman PJ, Lucia SM, Coltman CA, Thompson IM.  2008.  Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach.. Cancer prevention research (Philadelphia, Pa.). 1(3):174-81. Abstract
Song YJ, Tangen CM, Goodman P, Parnes HL, Lucia SM, Thompson IM, Kristal AR.  2008.  Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment.. The Prostate. 68(3):281-6. Abstract
Thompson IM, Tangen CM, Kristal AR.  2008.  Prostate-specific antigen: a misused and maligned prostate cancer biomarker.. Journal of the National Cancer Institute. 100(21):1487-8.
Thompson IM, Tangen CM, Ankerst DP, Chi C, Lucia SM, Goodman P, Parnes H, Coltman CA.  2008.  The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.. The Journal of urology. 180(2):544-7. Abstract
Sartor OA, Tangen CM, Hussain MHA, Eisenberger MA, Parab M, Fontana JA, Chapman RA, Mills GM, Raghavan D, Crawford DE.  2008.  Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).. Cancer. 112(11):2393-400. Abstract
Swanson GP, Goldman B, Tangen CM, Chin J, Messing E, Canby-Hagino E, Forman JD, Thompson IM, Crawford DE.  2008.  The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794.. The Journal of urology. 180(6):2453-7;discussion2458. Abstract
Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford DE.  2008.  Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.. Cancer. 112(10):2181-7. Abstract
Thompson IM, Tangen CM, Lucia SM.  2008.  The Prostate Cancer Prevention Trial and the future of chemoprevention.. BJU international. 101(8):933-4.
Flaig TW, Tangen CM, Hussain MHA, Stadler WM, Raghavan D, Crawford DE, Glodé ML.  2008.  Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(9):1532-6. Abstract
Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR.  2008.  Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial.. The Prostate. 68(13):1477-86. Abstract
2009
Thompson IM, Tangen CM, Paradelo J, Lucia SM, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G et al..  2009.  Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial.. The Journal of urology. 181(3):956-62. Abstract
Thompson IM, Tangen CM, Goodman PJ, Lucia SM, Klein EA.  2009.  Chemoprevention of prostate cancer.. The Journal of urology. 182(2):499-507;discussion508. Abstract
deVere White RW, Lara PN, Goldman B, Tangen CM, Smith DC, Wood DP, Hussain MHA, Crawford DE.  2009.  A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group trial (S0219).. The Journal of urology. 181(6):2476-80;discussion2480-1. Abstract
Lara PN, Tangen CM, Conlon SJ, Flanigan RC, Crawford DE.  2009.  Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949.. The Journal of urology. 181(2):512-6;discussion516-7. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Thompson IM.  2009.  Serum adiponectin, C-peptide and leptin and risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial.. The Prostate. 69(12):1303-11. Abstract
Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford DE.  2009.  Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer.. Urologic oncology. 27(2):155-9. Abstract
Gong Z, Kristal AR, Schenk JM, Tangen CM, Goodman PJ, Thompson IM.  2009.  Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial.. Cancer. 115(16):3661-9. Abstract
Hussain M, Goldman B, Tangen CM, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK et al..  2009.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(15):2450-6. Abstract
2010
Hoque A, Ambrosone CB, Till C, Goodman PJ, Tangen CM, Kristal AR, Lucia S, Wang Q, Kappil M, Thompson I et al..  2010.  Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial.. Cancer prevention research (Philadelphia, Pa.). 3(4):478-83. Abstract
Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia SM, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML et al..  2010.  Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.. Cancer prevention research (Philadelphia, Pa.). 3(12):1523-33. Abstract
Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW et al..  2010.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.. The Journal of urology. 184(6):2297-302. Abstract
Schenk JM, Kristal AR, Neuhouser ML, Tangen CM, White E, Lin DW, Kratz M, Thompson IM.  2010.  Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial.. American journal of epidemiology. 171(5):571-82. Abstract
2011
Schenk JM, Kristal AR, Arnold KB, Tangen CM, Neuhouser ML, Lin DW, White E, Thompson IM.  2011.  Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial.. American journal of epidemiology. 173(12):1419-28. Abstract
Scosyrev E, Ely BW, Messing EM, Speights VO, Grossman BH, Wood DP, deVere White RW, Vogelzang NJ, Trump DL, Natale RB et al..  2011.  Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU international. 108(5):693-699. Abstract